Ameritas Advisory Services LLC Buys 4,018 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Ameritas Advisory Services LLC sharply increased its Thermo Fisher Scientific stake in the fourth quarter, buying 4,018 additional shares and lifting its holdings to 4,783 shares worth about $2.77 million.
• Thermo Fisher reported better-than-expected quarterly results, with EPS of $5.44 versus $5.25 expected and revenue of $11.01 billion, up 6.2% year over year. The company also issued FY2026 EPS guidance of 24.640-25.120.
• Shares were trading down 2.8% at $446.50, while analysts remained broadly positive with a consensus Buy rating and a price target of $619.65. The company also raised its quarterly dividend to $0.47 per share from $0.43.

Ameritas Advisory Services LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 525.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,783 shares of the medical research company's stock after acquiring an additional 4,018 shares during the quarter. Ameritas Advisory Services LLC's holdings in Thermo Fisher Scientific were worth $2,771,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Howard Capital Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company's stock worth $1,791,000 after acquiring an additional 16 shares during the last quarter. Petros Family Wealth LLC lifted its stake in shares of Thermo Fisher Scientific by 3.9% in the 4th quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company's stock valued at $264,000 after acquiring an additional 17 shares during the last quarter. Salomon & Ludwin LLC boosted its holdings in Thermo Fisher Scientific by 1.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock valued at $669,000 after acquiring an additional 17 shares during the period. Financial Management Network Inc. grew its position in Thermo Fisher Scientific by 3.7% during the 3rd quarter. Financial Management Network Inc. now owns 511 shares of the medical research company's stock worth $248,000 after acquiring an additional 18 shares during the last quarter. Finally, Pallas Capital Advisors LLC lifted its position in Thermo Fisher Scientific by 1.5% in the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company's stock valued at $728,000 after purchasing an additional 18 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company's stock, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.33% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on TMO. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a "strong-buy" rating in a research report on Friday, April 24th. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research note on Friday, April 24th. Barclays cut their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 14th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Finally, UBS Group reiterated a "neutral" rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $619.65.

Thermo Fisher Scientific Trading Down 2.8%

NYSE:TMO opened at $446.50 on Thursday. The stock has a market cap of $165.93 billion, a price-to-earnings ratio of 24.55, a PEG ratio of 2.03 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The company's 50 day moving average price is $488.70 and its 200-day moving average price is $543.73. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion for the quarter, compared to analysts' expectations of $10.86 billion. During the same period last year, the firm posted $5.15 earnings per share. Thermo Fisher Scientific's revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.